Executive Briefing Series (formerly The Food & Drug Letter)

For the U.S. to speed new drugs to market and retain its innovative lead, the “FDA should approve drugs based on safety and leave efficacy testing for postmarket studies,” former commissioner Andrew von Eschenbach proposed in a recent opinion piece in The Wall Street Journal.